Jones Collombin Investment Counsel Has Lifted Bank N S Halifax (BNS) Stake; DANDRIT BIOTECH USA (DDRT) Sellers Decreased By 16.67% Their Shorts

DANDRIT BIOTECH USA INCORPORATED (OTCMKTS:DDRT) had a decrease of 16.67% in short interest. DDRT’s SI was 500 shares in January as released by FINRA. Its down 16.67% from 600 shares previously. With 3,700 avg volume, 0 days are for DANDRIT BIOTECH USA INCORPORATED (OTCMKTS:DDRT)’s short sellers to cover DDRT’s short positions. The stock increased 8.75% or $0.35 during the last trading session, reaching $4.35. About shares traded. DanDrit Biotech USA, Inc. (OTCMKTS:DDRT) has 0.00% since January 26, 2017 and is . It has underperformed by 16.70% the S&P500.

Jones Collombin Investment Counsel Inc increased Bank N S Halifax (BNS) stake by 501.75% reported in 2017Q3 SEC filing. Jones Collombin Investment Counsel Inc acquired 91,870 shares as Bank N S Halifax (BNS)’s stock declined 10.69%. The Jones Collombin Investment Counsel Inc holds 110,180 shares with $7.09 million value, up from 18,310 last quarter. Bank N S Halifax now has $78.22 billion valuation. The stock decreased 0.21% or $0.14 during the last trading session, reaching $66.21. About 858,697 shares traded or 53.76% up from the average. The Bank of Nova Scotia (NYSE:BNS) has risen 16.52% since January 26, 2017 and is uptrending. It has underperformed by 0.18% the S&P500.

DanDrit Biotech USA, Inc., a biotechnology company, focuses on developing a vaccine for the treatment of colorectal cancer primarily in the United States, Europe, and Asia. The company has market cap of $59.72 million. The companyÂ’s products include MelCancerVac for the treatment of cancer which is in one phase I/II trial in Denmark and two phase II trials in Denmark and Singapore; Tolerogenic dendritic cell, which is in pre-clinical stage in Denmark; and Melvaccine, a melanoma cell lysate used as stand-alone vaccine that is in pre-clinical state in Denmark. It currently has negative earnings. The firm has a collaboration agreement with Fondazione GISCAD; and with Riyadh Pharma to promote cooperation in the manufacturing and marketing of dendritic cell cancer vaccine.

Among 9 analysts covering The Bank Of Nova Scotia (NYSE:BNS), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. The Bank Of Nova Scotia has $87 highest and $61 lowest target. $71.57’s average target is 8.10% above currents $66.21 stock price. The Bank Of Nova Scotia had 17 analyst reports since August 4, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, August 29 by Canaccord Genuity. RBC Capital Markets maintained the stock with “Outperform” rating in Monday, August 31 report. As per Wednesday, December 2, the company rating was maintained by RBC Capital Markets. On Thursday, June 9 the stock rating was downgraded by Macquarie Research to “Neutral”. The rating was initiated by Dundee Securities with “Buy” on Wednesday, September 21. The stock of The Bank of Nova Scotia (NYSE:BNS) earned “Overweight” rating by Barclays Capital on Tuesday, May 23. The firm earned “Outperform” rating on Wednesday, August 31 by RBC Capital Markets. As per Wednesday, May 31, the company rating was maintained by RBC Capital Markets. The firm earned “Buy” rating on Friday, August 28 by Canaccord Genuity.